- Home
- EFSI vs ACTU Comparison
EFSI vs ACTU Comparison
Compare EFSI & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFSI
- ACTU
- Stock Information
- Founded
- EFSI 1881
- ACTU 2015
- Country
- EFSI United States
- ACTU United States
- Employees
- EFSI N/A
- ACTU N/A
- Industry
- EFSI Major Banks
- ACTU
- Sector
- EFSI Finance
- ACTU
- Exchange
- EFSI Nasdaq
- ACTU NYSE
- Market Cap
- EFSI 159.9M
- ACTU 135.0M
- IPO Year
- EFSI N/A
- ACTU 2024
- Fundamental
- Price
- EFSI $30.71
- ACTU $9.09
- Analyst Decision
- EFSI Strong Buy
- ACTU Strong Buy
- Analyst Count
- EFSI 2
- ACTU 1
- Target Price
- EFSI $40.00
- ACTU $20.00
- AVG Volume (30 Days)
- EFSI 15.4K
- ACTU 72.4K
- Earning Date
- EFSI 04-25-2025
- ACTU 05-15-2025
- Dividend Yield
- EFSI 4.06%
- ACTU N/A
- EPS Growth
- EFSI N/A
- ACTU N/A
- EPS
- EFSI 1.52
- ACTU N/A
- Revenue
- EFSI $58,067,000.00
- ACTU N/A
- Revenue This Year
- EFSI $3.16
- ACTU N/A
- Revenue Next Year
- EFSI $22.35
- ACTU N/A
- P/E Ratio
- EFSI $20.08
- ACTU N/A
- Revenue Growth
- EFSI N/A
- ACTU N/A
- 52 Week Low
- EFSI $28.83
- ACTU $5.51
- 52 Week High
- EFSI $36.93
- ACTU $11.99
- Technical
- Relative Strength Index (RSI)
- EFSI N/A
- ACTU N/A
- Support Level
- EFSI N/A
- ACTU N/A
- Resistance Level
- EFSI N/A
- ACTU N/A
- Average True Range (ATR)
- EFSI 0.00
- ACTU 0.00
- MACD
- EFSI 0.00
- ACTU 0.00
- Stochastic Oscillator
- EFSI 0.00
- ACTU 0.00
About EFSI Eagle Financial Services Inc Common Stock
Eagle Financial Services Inc is a locally owned and managed financial institution. It offers retail and commercial banking services, including demand, savings and time deposits and consumer, mortgage, and commercial loans. It also offers telephone banking, internet banking, and mobile banking to its customers. The Company has three reportable operating segments, Community Banking, Marine Lending and Wealth Management. It generates a majority of its revenue from the Community Banking segment.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.